Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (Kelun-Biotech or the Company, 6990.HK) announced that results from both ...

SCLC, addressing a high-relapse setting with limited second-line efficacy and modest survival benefit. Ifinatamab deruxtecan ...

Trastuzumab pamirtecan, being developed under a 2023 partnership between BioNTech and DualityBio, elicited a 44.1% overall ...

DNADX high scores predicted improved PFS, supporting genomic instability and DNA repair deficiency as biologically relevant ...

Phase 1/2 RAINFOL™-01 data showed the combination ofrinatabart sesutecan (Rina-S®) and bevacizumab was tolerable, with no new safety signals in patients with advanced ovarian c ...

The Phase II cohort analysis included 145 patients whose conditions had progressed following initial chemotherapy.

This antibody-drug conjugate targets a specific protein associated with poor prognosis in patients whose disease progressed after platinum-based chemotherapy.

At AACR 2026, the Genialis™ Supermodel–powered RNA survival model outperforms standard of care in real-world clinical data, establishing a scalable biomarker framework for ADC drug developmentBOSTON-- ...

Lung01 Phase 2 trial, with support from IDeate-PanTumor01 Phase 1/2 trialIf approved, ifinatamab deruxtecan would be a first-in-class B7-H3 directed DXd antibody drug conjugate for these patients ...

Sixteen months after partnering with Tubulis, Gilead has decided to acquire the biotech and its portfolio of ADCs.

Gilead's $5B Tubulis deal expands its ADC pipeline, boosting oncology ambitions as the company accelerates strategic ...

MUC16 is highly and stably expressed in the most aggressive and most common subtypes of endometrial cancer Findings support Whitehawk's development of MUC16-directed ADC, HWK-016, currently being ...